Cite
HARVARD Citation
Garcia-Manero, G. et al. (n.d.). 99 CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS)-DEFINED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS). Leukemia research. 39 (1), pp. S50-S51. [Online].